# Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

> **NCT05176717** · PHASE2,PHASE3 · TERMINATED · sponsor: **Laboratoires Thea** · enrollment: 5 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders

## Interventions

- **DRUG:** QR-421a
- **OTHER:** Sham-procedure

## Key facts

- **NCT ID:** NCT05176717
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176717, "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05176717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*